ArticleTranslational psychiatry2014
Blood transcriptomic biomarkers in adult primary care patients with major depressive disorder undergoing cognitive behavioral therapy.
Article in Translational psychiatry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 83 citations in OpenAlex.
- Trial
- Molecular Signatures of Blood Biomarkers in Depression: Gene Expression Analysis ofDiagnostics (Basel, Switzerland) · 2026Article
- Peripheral blood CADM1 expression and multi-gene signatures in depressive disorders: a pilot case-control study from the United Arab Emirates.Frontiers in psychiatry · 2026Article
- A Mutation in the Transmembrane Domain of Adenylate Cyclase 3 Impairs Enzymatic Function to Cause Sex-Specific Depression- and Anxiety-Like Behaviors and Food Seeking in a Rat Model.Genes, brain, and behavior · 2025Article
- Cognitive-behavioral therapy to normalize social learning for patients with major depressive disorders: study protocol for a single-arm clinical trial.BMC psychology · 2025Article
- Protein-coding mutation in Adcy3 increases adiposity and alters emotional behaviors sex-dependently in rats.Obesity (Silver Spring, Md.) · 2025Article
- Transcriptomics and psychotherapy: An integrative review.Brain, behavior, & immunity - health · 2024Review
- Protein-coding mutation inbioRxiv : the preprint server for biology · 2024Article
- Adenylate cyclase 3: a potential genetic link between obesity and major depressive disorder.Physiological genomics · 2024Review
- Biomarker-Guided Tailored Therapy in Major Depression.Advances in experimental medicine and biology · 2024Review
- The Wistar Kyoto Rat: A Model of Depression Traits.Current neuropharmacology · 2023Article
- Clinical Utility of Fluid Biomarker in Depressive Disorder.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2022Review
- Physiological roles of mammalian transmembrane adenylyl cyclase isoforms.Physiological reviews · 2022Review
- Identification of Key Modules and Genes Associated with Major Depressive Disorder in Adolescents.Genes · 2022Article
- GαFrontiers in pharmacology · 2022Review
- CaFrontiers in pharmacology · 2022Review
- Biological Diagnosis of Depression: A Biomarker Panel from Several Nonspecial Indicators Instead of the Specific Biomarker(s).Neuropsychiatric disease and treatment · 2022Article
- Genome-wide DNA methylation and gene expression analyses in monozygotic twins identify potential biomarkers of depression.Translational psychiatry · 2021Article
- Whole genome sequencing of nearly isogenic WMI and WLI inbred rats identifies genes potentially involved in depression and stress reactivity.Scientific reports · 2021Article
- Predicting tissue-specific gene expression from whole blood transcriptome.Science advances · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
An objective, laboratory-based diagnostic tool could increase the diagnostic accuracy of major depressive disorders (MDDs), identify factors that characterize patients and promote individualized therapy. The goal of this study was to assess a blood-based biomarker panel, which showed promise in adolescents with MDD, in adult primary care patients with MDD and age-, gender- and race-matched nondepressed (ND) controls. Patients with MDD received cognitive behavioral therapy (CBT) and clinical assessment using self-reported depression with the Patient Health Questionnaire-9 (PHQ-9). The measures, including blood RNA collection, were obtained before and after 18 weeks of CBT. Blood transcript levels of nine markers of ADCY3, DGKA, FAM46A, IGSF4A/CADM1, KIAA1539, MARCKS, PSME1, RAPH1 and TLR7, differed significantly between participants with MDD (N=32) and ND controls (N=32) at baseline (q< 0.05). Abundance of the DGKA, KIAA1539 and RAPH1 transcripts remained significantly different between subjects with MDD and ND controls even after post-CBT remission (defined as PHQ-9 <5). The ROC area under the curve for these transcripts demonstrated high discriminative ability between MDD and ND participants, regardless of their current clinical status. Before CBT, significant co-expression network of specific transcripts existed in MDD subjects who subsequently remitted in response to CBT, but not in those who remained depressed. Thus, blood levels of different transcript panels may identify the depressed from the nondepressed among primary care patients, during a depressive episode or in remission, or follow and predict response to CBT in depressed individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.